OTCMKTS:MRMD - MariMed Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.25
  • Forecasted Upside: 177.78 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.81
▼ -0.0299 (-3.56%)

This chart shows the closing price for MRMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MariMed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRMD

Analyst Price Target is $2.25
▲ +177.78% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for MariMed in the last 3 months. The average price target is $2.25, with a high forecast of $2.25 and a low forecast of $2.25. The average price target represents a 177.78% upside from the last price of $0.81.

This chart shows the closing price for MRMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in MariMed.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/15/2021Colliers SecuritiesInitiated CoverageBuy$2.25
(Data available from 1/19/2017 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2021
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2021
  • 11 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/22/2021
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/21/2021
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2021
  • 8 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/20/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/19/2022

Current Sentiment

  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
MariMed logo
MariMed, Inc. engages in direct owning of cannabis licenses and management of seed-to-sale operations. It focuses on the development, operation, management, and optimization of facilities for the cultivation, production, and dispensing of medicinal and recreational cannabis and cannabis-infused products. The company was founded by Robert N. Fireman and Jon Levine on January 25, 2011 and is headquartered in Norwood, MA.
Read More

Today's Range

Now: $0.81
Low: $0.81
High: $0.85

50 Day Range

MA: $0.79
Low: $0.67
High: $0.94

52 Week Range

Now: $0.81
Low: $0.60
High: $1.20

Volume

371,524 shs

Average Volume

444,460 shs

Market Capitalization

$270.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.54

Frequently Asked Questions

What sell-side analysts currently cover shares of MariMed?

The following Wall Street sell-side analysts have issued stock ratings on MariMed in the last year: Colliers Securities.
View the latest analyst ratings for MRMD.

What is the current price target for MariMed?

1 Wall Street analysts have set twelve-month price targets for MariMed in the last year. Their average twelve-month price target is $2.25, suggesting a possible upside of 177.8%. Colliers Securities has the highest price target set, predicting MRMD will reach $2.25 in the next twelve months. Colliers Securities has the lowest price target set, forecasting a price of $2.25 for MariMed in the next year.
View the latest price targets for MRMD.

What is the current consensus analyst rating for MariMed?

MariMed currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRMD will outperform the market and that investors should add to their positions of MariMed.
View the latest ratings for MRMD.

What other companies compete with MariMed?

How do I contact MariMed's investor relations team?

MariMed's physical mailing address is 11 ROYAL ROAD, BROOKLINE MA, 02445. The company's listed phone number is (617) 795-5140 and its investor relations email address is [email protected] The official website for MariMed is marimedadvisors.com.